Bernstein Initiation of China CDMO Coverage: Complex Molecules Will Drive Growth in the Next Decade

Overview

Bernstein initiates coverage on the China CDMO segment, with a core view that rising global pharmaceutical R&D spending, higher outsourcing penetration, and ramping complex new drug modalities will push CDMOs into a structurally growthful phase. The report covers WuXi AppTec, Asymchem, and WuXi Biologics, with WuXi AppTec as the preferred pick, Asymchem as a high-growth option, and WuXi Biologics as a more balanced risk-reward name due to commercialization manufacturing competitiveness and geopolitical risk.

Core views

The report believes that while traditional small molecules and monoclonal antibodies remain the largest drug market, most incremental growth will increasingly come from peptides, complex small molecules, ADCs, bispecific/multispecific antibodies, DNA/RNA therapies, and cell and gene therapies. These modalities are more difficult to manufacture and therefore require specialized chemistry, biologics, analytics, and compliance capabilities, which should raise outsourcing penetration and client stickiness. Through global client relationships, offshore revenue mix, cross-region capacity deployment, and ongoing capex, leading Chinese CDMOs have evolved from domestic service providers into critical participants in the global supply chain.

Analysis framework

The report applies industry growth frameworks, modality segmentation, global peer benchmarking, revenue and profit forecasting, ROIC and capex cycle analysis, geopolitical policy risk assessment, and valuation methods to provide first-time coverage and relative ranking for the three Chinese CDMOs. WuXi AppTec is primarily valued with DCF and P/E, WuXi Biologics with DCF and EV/EBITDA, and Asymchem with P/E.

Methodology notes

• industry_growthmodality-driven CDMO growth framework

  Modality-driven CDMO growth

  The drug market is split by modalities into traditional small molecules, monoclonal antibodies, peptides, ADCs, bispecific/multispecific antibodies, and DNA/RNA therapies, assessing that high-complexity, high-growth modalities will generate stronger outsourcing demand and tougher CDMO moats.

• company_benchmarkingROIC and capacity cycle comparison

  Capital return and capacity cycle comparison

  The report compares ROIC, capex intensity, capacity utilization, and global capacity deployment to assess operating quality across CDMOs, and concludes that WuXi AppTec has the strongest capital return profile in the peer set.

• Valuation methodsDCF, P/E and EV/EBITDA valuation

  Multi-method valuation

  Different valuation approaches, including DCF, P/E, or EV/EBITDA, are cross-checked across companies to derive target prices, reflecting differences in business maturity, earnings visibility, and peer valuation context.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• WuXi AppTec

  Preferred name; Outperform; Top Pick

  Strengths

  End-to-end CRDMO platform, leadership in small molecules and peptides, strong conversion from early-stage to commercialization, global capacity footprint and strong cost control, and ROIC near 40%.

  Weaknesses

  It experienced growth stagnation in 2023-2024 and faces geopolitical policy uncertainty related to the BIOSECURE Act and DoD 1260H.

  Comparison

  Compared with Chinese and global CDMO peers, the report finds WuXi AppTec has the best ROIC, scale, modality coverage, and asset utilization.

  Risks

  Geopolitical risk, US policy, client outsourcing pacing, capex return, and complex-modality demand not meeting expectations.

• Asymchem

  High-growth name; Outperform

  Strengths

  Near an inflection point after the Paxlovid cycle, small-molecule CDMO growth is stabilizing with order flow, commercialization production, and utilization recovery; its peptide business is expanding quickly and could become an important peptide manufacturing player after WuXi AppTec.

  Weaknesses

  Much smaller scale than WuXi AppTec, higher execution risk, and growth is more dependent on small-molecule recovery and peptide expansion delivery.

  Comparison

  The report sees it as having the fastest revenue and profit growth among the covered companies, but weaker quality and certainty than WuXi AppTec.

  Risks

  Commercial volume ramp may be slower than expected, peptide competition intensifies, utilization remains below target, and profit recovery may underperform.

• WuXi Biologics

  China's leading biopharma CRDMO; Market-Perform

  Strengths

  China's leading biopharma CRDMO with strong early-stage development capabilities and a global biologics capacity network, benefiting from biopharma, ADC, and bispecific/multispecific antibody growth.

  Weaknesses

  The business is more weighted to early-stage programs, and late-stage and commercialization manufacturing leadership trails Lonza and Samsung Biologics; ADC growth may decelerate.

  Comparison

  Compared with WuXi AppTec, small-molecule commercialization leadership is not yet established; compared with global commercialization biopharma manufacturing leaders, differentiation is insufficient.

  Risks

  ADC demand-supply disruptions, weaker commercialization program conversion, capex pressure from capacity, and biopharma supply-chain localization and geopolitical risk.

Key data

• Global pharmaceutical R&D spendingAbout $278bn in 2024, about $476bn in 2034EThe report expects global biopharma R&D spending to grow at around 6% CAGR.
• Outsourcing penetrationAbout 52% rising to above 65%Rising outsourcing penetration is a key driver behind global CDMO growth outpacing overall R&D spending.
• High-growth modalitiesPeptides around 15% CAGR; ADCs and bispecific antibodies around 23% CAGR; DNA/RNA and CGT up to 30%+ CAGRThese newer modalities grow materially faster than traditional small molecules and monoclonal antibodies.
• Overseas revenue share of leading Chinese CDMOsWuXi AppTec about 87%, WuXi Biologics about 88%, Asymchem about 74% (2025)Shows that Chinese CDMOs have become participants in the global outsourcing supply chain.
• WuXi AppTec revenue forecastCNY45bn (2025) to CNY100bn (2030E)Driven by small molecules, peptides, and complex modalities.
• Asymchem revenue forecastAbout CNY7bn (2025) to CNY24bn (2030E)Implied CAGR is about 27%, and the report describes it as the fastest-growing company among the three.
• WuXi Biologics revenue forecastCNY22bn (2025) to CNY45bn (2030E)Growth is driven by biopharma, ADCs, and bispecific/multispecific antibodies, but commercialization manufacturing competitiveness still needs validation.
• Target price603259.CH CNY168; 2359.HK HKD204; 002821.CH CNY198; 6821.HK HKD157; 2269.HK HKD42From the report valuation table.

Impact & implications

The investment implication is that the opportunity in Chinese CDMOs is not just Chinese pharmaceutical outsourcing, but an upgrade in global complex drug manufacturing outsourcing. WuXi AppTec is more about quality and compounding returns, suitable for gaining exposure to long-term structural growth in China CDMO; Asymchem is more about high-growth optionality and peptide exposure; WuXi Biologics still has biopharma platform value, but relative upside is constrained by commercialization manufacturing capability, ADC demand-supply changes, and geopolitical risk.

Risks

• Uncertainty around the BIOSECURE Act and US policy could affect client acquisition and long-term order books for Chinese CDMOs.
• WuXi AppTec's inclusion on the DoD 1260H list and related litigation may take years to fully materialize but still creates valuation and client-confidence pressure.
• Biopharma supply chains are harder to geographically diversify than chemical manufacturing, so WuXi Biologics faces higher localization and geopolitical risk.
• ADC pipeline growth may peak in 2023-2025, and supply-demand disturbances in manufacturing could weaken WuXi Biologics' growth momentum.
• If demand for complex modalities, outsourcing penetration, or commercialization conversion comes in lower than expected, revenue and profit forecasts will be affected.
• If sustained capex does not translate into high utilization and high ROIC, it could weigh on industry returns.

What to watch

• Order growth in peptides, GLP-1, complex small molecules, ADCs, and bispecific/multispecific antibodies.
• The conversion rate of WuXi AppTec projects from early development to Phase 3 and commercialization manufacturing.
• Asymchem small-molecule CDMO backlog, PPQ activity, commercialization ramp, and peptide revenue realization.
• Whether WuXi Biologics' late-stage and commercialization program mix rises, and whether it can challenge commercialization manufacturing leaders such as Lonza and Samsung Biologics.
• Progress on the BIOSECURE Act, DoD 1260H, Medicaid exceptions, and other US policy developments.
• Changes in overseas revenue share, global capacity utilization, capex intensity, and ROIC.